Navigation Links
Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results
Date:9/1/2011

SAINT PAUL, Minn., Sept. 1, 2011 /PRNewswire/ -- Angeion Corporation (NASDAQ: ANGN) today reported financial results for its fiscal third quarter ended July 31, 2011.

Angeion reported revenues of $6.8 million compared to $7.1 million in the third quarter of fiscal 2010. Angeion incurred a net loss of $81,000, or $(0.02) per diluted share versus net income of $126,000, or $0.03 per diluted share in the comparable quarter last year. Financial results for Q3 2011 were impacted by severance charges and associated legal and consulting fees attributable to the departure of the previous chief executive officer.

Gross margin for the quarter remained solid at 57.6%, comparable to the 57.8% gross margin in the third quarter of fiscal year 2010. General and administrative expenses in Q3 2011 decreased 20% versus the prior year comparable quarter due to lower severance expenses in the just completed quarter versus the prior year third quarter. Management will continue to examine overhead expenses going forward to move the company on a path toward profitability. Sales and marketing expenses were essentially the same compared to the third quarter of fiscal 2010 and research and development costs increased 32% as management dedicated additional resources to advance software and hardware development initiatives to enhance current product offerings and develop future new products.

“Bringing stability to Angeion as an operating company is well underway,” said Gregg O. Lehman, Ph.D., President and Chief Executive Officer of Angeion Corporation. “Change is needed to become a consistently profitable company and we are examining every aspect of the Company to determine where improvements need to be made. Angeion has been impacted in recent years by changes in its management resulting in multiple severance and related charges. We are now realizing stability and hav
'/>"/>

SOURCE Angeion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Angeion Corporation to Report Third Quarter Fiscal Year 2011 Financial Results on Thursday, September 1, 2011
2. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
3. CEL-SCI Corporation Releases Letter to Shareholders
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
7. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
8. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
9. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
11. Immunosyn Corporation Releases SF-1019 Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 Kinex Pharmaceuticals announced today that ... Roswell Park Cancer Institute. KX2-361 (KX02), a ... has shown potent inhibitory activity against a broad panel ... resistant to Temozolomide (T98G), the most widely used chemotherapy ... brain tumor mouse model, KX2-361 consistently clears brain tumors ...
(Date:12/24/2014)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ), the ... Jennifer Hagerman , Pharm.D., AE-C, senior director of ... the president of the Michigan Pharmacists Association on Jan. ... Feb. 28, 2015, at the MPA Annual Convention and ... in Detroit, Michigan . Hagerman will ...
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... showed patients taking prasugrel had lower ... stroke or cardiovascular death after first event than ... A new,pre-specified analysis of the landmark Phase III ... acute coronary syndromes,(ACS) managed with an artery-opening procedure known ...
... 21 Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today ... in the United Kingdom has authorized a Phase 1,study ... lead product candidate for the treatment of gout., ... 1 study of,RDEA594, within six months from designation as ...
Cached Medicine Technology:Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 2Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 3Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 4Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 5Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial 2Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial 3Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial 4
(Date:12/26/2014)... India Network Foundation, a non-profit US ... announced today a new version of “ EasySelect ”, ... right plan for their visiting parents. The technology tool ... selection process when choosing an insurance plan by showing ... a few clicks. Many elderly Asian Indian parents often ...
(Date:12/25/2014)... 26, 2014 This is a professional ... global Sterilizers industry with a focus on the Chinese ... status of the Sterilizers manufacturers and is a valuable ... interested in the industry. This report provides a basic ... manufacturing technology. In this part, the report presents the ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and ... Today, the company announces big discounts on its ... colors. , BambooFlooringChina.com is the world’s leader in bamboo ... valid until Jan. 20, 2015. , The bamboo mats ... a natural thread. All the bamboo strips for the ...
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- The risk of ... holidays, so you need to be extra cautious, an ... we see a significant increase in patients coming in ... the Suffolk County Volunteer Firefighters Burn Center of Stony ... should be full of joy, but if not careful, ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Don't Let Burns Mar Your Holidays 2
... At the 14th annual retrovirus conference in Los Angeles, it ... the United States//. According to Harold Jaffe, a professor of ... no signs of decreasing. ,He also ... fresh infection of HIV cases. Jaffe emphasized on the scientific ...
... to a latest study, the ages at which teenagers and ... a significant impact on their delinquent behavior//. The level of ... earlier than their peer group and vice versa. ... of Youth and Adolescence. Stacy Armour the co-author of this ...
... Inc. today announced the first patient implant in a ... near the spinal cord will control// chronic chest pain ... is the first person to receive this investigational device, ... approximately 1.3 million Americans who suffer from chronic angina, ...
... of Technology researchers have engineered a way to deliver ... as carriers. The breakthrough could lead to low fat ... in fat-containing foods, and could be used to enrich ... ,The team, led by Dr. Yoav ...
... be in gold nanoparticles - tiny pieces of gold so ... potential of gold nanoparticles has been hindered by the difficulty ... be injected into a patient. New research at the University ... used to overcome this problem, creating a new type of ...
... the world's leading pharmaceutical companies, issued a press release ... metastatic prostate cancer. ,A Phase III ... to Novantrone (mitoxantrone) plus prednisone. The study included a ... spread of disease after hormonal therapy., ,The results ...
Cached Medicine News:Health News:Spinal Cord Stimulation Pilot Study for Chronic Angina 2Health News:Natural Milk Protein Could Lead to Super Nutritious Foods 2Health News:Common Ingredient in Big Macs and Sodas Can Stabilize Gold Nanoparticles for Medical Use 2Health News:Common Ingredient in Big Macs and Sodas Can Stabilize Gold Nanoparticles for Medical Use 3
These retractors are packaged singly ready for sterilization at your facility....
These retractors are packaged singly ready for sterilization at your facility....
HemoNIR™ is a portable device that measures the ability of apersons blood to carry oxygen by monitoring functional vs. non functional hemoglobin....
... aureus and methicillin resistant coagulase-negative staphylococci in ... MRSA Latex Kit for PBP2/ detects Penicillin ... Staphylococcus aureus and coagulase-negative staphylococci. PBP2/ is ... and is present in the membranes of ...
Medicine Products: